These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28238095)

  • 21. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
    Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
    J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.
    Xu X; He Y; Miao X; Wu Y; Han J; Wang Q; Liu J; Zhong F; Ou Y; Wang Y; He S
    Leuk Res; 2016 Aug; 47():54-62. PubMed ID: 27258734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma].
    Furukawa Y; Kikuchi J
    Rinsho Ketsueki; 2016 May; 57(5):546-55. PubMed ID: 27263778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
    Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
    Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
    Nakagawa Y; Nakayama H; Nagata M; Yoshida R; Kawahara K; Hirosue A; Tanaka T; Yuno A; Matsuoka Y; Kojima T; Yoshitake Y; Hiraki A; Shinohara M
    Int J Oncol; 2014 Apr; 44(4):1376-84. PubMed ID: 24452447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
    Shen Y; Sun Y; Zhang L; Liu H
    Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
    Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
    Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR).
    Wang Y; Huang Y; Xu X; Tang J; Huang X; Zhu J; Liu J; Miao X; Wu Y; Yang F; Ji L; He S
    Leuk Res; 2014 Aug; 38(8):955-63. PubMed ID: 24974147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
    Tsubaki M; Takeda T; Yoshizumi M; Ueda E; Itoh T; Imano M; Satou T; Nishida S
    Tumour Biol; 2016 Jul; 37(7):9099-110. PubMed ID: 26762414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
    Xie X; Tang SC; Cai Y; Pi W; Deng L; Wu G; Chavanieu A; Teng Y
    Oncotarget; 2016 Sep; 7(36):58111-58120. PubMed ID: 27517156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of Capon in multiple myeloma.
    Shen Y; Liu H; Gu S; Wei Z; Liu H
    Tumour Biol; 2017 Jul; 39(7):1010428317713674. PubMed ID: 28671047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas.
    Zhu X; Miao X; Wu Y; Li C; Guo Y; Liu Y; Chen Y; Lu X; Wang Y; He S
    Exp Cell Res; 2015 Jul; 335(2):216-23. PubMed ID: 26024773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
    Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
    Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.
    Ouyang Y; Zhong F; Wang Q; Ding L; Zhang P; Chen L; Wang Y; Cheng C
    Leuk Res; 2016 Nov; 50():104-111. PubMed ID: 27701018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4.
    Wu Y; Zhu X; Shen R; Huang J; Xu X; He S
    Pathol Res Pract; 2019 Nov; 215(11):152603. PubMed ID: 31540771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.
    Münzberg C; Höhn K; Krndija D; Maaß U; Bartsch DK; Slater EP; Oswald F; Walther P; Seufferlein T; von Wichert G
    J Cell Mol Med; 2015 May; 19(5):948-59. PubMed ID: 25754106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells.
    Lewis-Saravalli S; Campbell S; Claing A
    Cell Signal; 2013 Sep; 25(9):1813-9. PubMed ID: 23707487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell adhesion downregulates the expression of Homer1b/c and contributes to drug resistance in multiple myeloma cells.
    Tang J; Zhou H; Wang C; Fei X; Zhu L; Huang Y; He Y; Liu J; Miao X; Wu Y; Wang Y
    Oncol Rep; 2016 Mar; 35(3):1875-83. PubMed ID: 26718835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
    Hu Q; Wang M; Wang J; Tao Y; Niu T
    Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
    Li X; Yang Y; Yi X
    Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.